Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab.
1 other identifier
observational
841
1 country
1
Brief Summary
Relationships of B-cell Activating Factor Gene Polymorphisms With ulcerative colitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedFirst Submitted
Initial submission to the registry
April 27, 2026
CompletedFirst Posted
Study publicly available on registry
May 4, 2026
CompletedMay 4, 2026
March 1, 2026
7.3 years
April 27, 2026
April 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the genotypes of BAFF
multiplex polymerase chain reaction-ligase detection reaction technique
Baseline
Study Arms (2)
UC Patients
Patients diagnosed with Ulcerative Colitis.
normal controls
gender- and age-matched normal controls
Eligibility Criteria
There was no statistically significant difference in the gender ratio, average age, and proportion of smokers between UC group and normal control group. All study subjects are from the Zhejiang Han population who are not related by blood.
You may qualify if:
- diagnosed UC based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results
You may not qualify if:
- rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
the Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
Biospecimen
Extract whole genome DNA from peripheral blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 27, 2026
First Posted
May 4, 2026
Study Start
March 1, 2018
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
May 4, 2026
Record last verified: 2026-03